Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
6 lessons
12mA goal-by-goal map of the peptides people ask about most, scored on human evidence and regulatory status. The only ones with strong evidence are approved drugs; most of the rest are animal data. No vendors, no dosing.
11mNo peptide is FDA-approved for building muscle in healthy adults. Here is what the human trials actually measured for growth hormone secretagogues, IGF-1 analogs, MOTS-c and the GLP-1 drugs, where each sits on the evidence ladder, and what regulators and anti-doping rules say.
8mPeptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.
8mNew 2026 data puts BPC-157 into a sharper recovery frame: oxidative stress, inflammation, apoptosis, angiogenesis, and the limits of animal evidence.
8mBPC-157 finally has a registered human sports-injury study. The signal is important, but it is not proof yet. Here is how to read the trial without the hype.
8mA new ECRI and ISMP warning says popular wellness peptides are being marketed faster than the evidence can support. Here is how to separate compound science from product risk.
Also available at /blog for legacy links.